C-terminal domain of SMYD3 serves as a unique HSP90-regulated motif in oncogenesis

Mark A. Brown; Kenneth Foreman; June Harriss; Chhaya Das; Li Zhu; Melissa Edwards; Salam Shaaban; Haley Tucker

doi:10.18632/oncotarget.2970

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

C-terminal domain of SMYD3 serves as a unique HSP90-regulated motif in oncogenesis

Mark A. Brown _, Kenneth Foreman, June Harriss, Chhaya Das, Li Zhu, Melissa Edwards, Salam Shaaban and Haley Tucker

PDF | HTML | How to cite

Oncotarget. 2015; 6:4005-4019. https://doi.org/10.18632/oncotarget.2970

Metrics: PDF 2669 views | HTML 2622 views | ?

Abstract

Mark A. Brown1,*, Kenneth Foreman2,*, June Harriss3, Chhaya Das3, Li Zhu3, Melissa Edwards1,3, Salam Shaaban4, Haley Tucker3

1Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80523, USA

2Coferon Inc., Stony Brook, NY 11791, USA

3University of Texas at Austin, Institute of Cellular and Molecular Biology, Austin, TX 78712, USA

4Abbvie, Worcester, MA 01605, USA

*These authors have contributed equally to this work

Correspondence to:

Haley Tucker, e-mail: [email protected]

Keywords: HSP90, SMYD3, tumorigenesis, lysine methylation, histone modifications

Received: August 08, 2014 Accepted: December 16, 2014 Published: March 02, 2015

ABSTRACT

The SMYD3 histone methyl transferase (HMTase) and the nuclear chaperone, HSP90, have been independently implicated as proto-oncogenes in several human malignancies. We show that a degenerate tetratricopeptide repeat (TPR)-like domain encoded in the SMYD3 C-terminal domain (CTD) mediates physical interaction with HSP90. We further demonstrate that the CTD of SMYD3 is essential for its basal HMTase activity and that the TPR-like structure is required for HSP90-enhanced enzyme activity. Loss of SMYD3-HSP90 interaction leads to SMYD3 mislocalization within the nucleus, thereby losing its chromatin association. This results in reduction of SMYD3-mediated cell proliferation and, potentially, impairment of SMYD3’s oncogenic activity. These results suggest a novel approach for blocking HSP90-driven malignancy in SMYD3-overexpressing cells with a reduced toxicity profile over current HSP90 inhibitors.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2970

Publication Alerts

Research Papers:

C-terminal domain of SMYD3 serves as a unique HSP90-regulated motif in oncogenesis

Abstract